Keywords: mgi/helsinn, aloxi, meets, ph, iii, endpoints, drugmaker

MGI/Helsinn's Aloxi meets Ph III endpoints

Article | 22 December 2006

Print This

US drugmaker MGI Pharma and partner Helsinn Healthcare SA, a privately-held Swiss pharmaceutical group, have completed two Phase III trials ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in